CDK
Los inhibidores de las quinasas dependientes de ciclina (CDK) son compuestos que bloquean la actividad de las CDK, un grupo de quinasas de proteínas que regulan el ciclo celular, la transcripción y otros procesos celulares. Las CDK se activan al unirse a las ciclinas, y su actividad es crucial para la progresión de las células a través de las diferentes fases del ciclo celular. Inhibir las CDK puede detener la división celular, provocando la detención del ciclo celular y la apoptosis, especialmente en células cancerosas donde las CDK a menudo están desreguladas. Los inhibidores de CDK se utilizan ampliamente en la investigación del cáncer y tienen un potencial terapéutico en el tratamiento de varios tipos de cáncer. En CymitQuimica, ofrecemos una selección completa de inhibidores de CDK de alta calidad para apoyar su investigación en el control del ciclo celular, el cáncer y el desarrollo terapéutico.
Se han encontrado 546 productos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
ZNL-05-044
ZNL-05-044, a CDK11 inhibitor, exhibits IC50 values of 0.23 μM for CDK11A and 0.27 μM for CDK11B, as determined by NanoBRET assay.Fórmula:C21H22Cl2N6OSPureza:98%Forma y color:SolidPeso molecular:477.41CDK4/6-IN-5
CAS:CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)Fórmula:C22H28ClFN6O4SForma y color:SolidPeso molecular:527.01NecroIr1
NecroIr1, an iridium(III) complex, induces necroptosis in Cisplatin-resistant lung cells, targeting mitochondria and disrupting MMP.Fórmula:C40H29ClIrN5OForma y color:SolidPeso molecular:823.36CDK7/9-IN-1
CAS:CDK7/9-IN-1 inhibits CDK7/9 with IC50: 0.0656 μM (no pre-incubation), 0.00574 μM (3h pre-inc.), and CDK9: 2.14 μM (3h pre-inc.) for cancer research.Fórmula:C24H32F3N5O2Forma y color:SolidPeso molecular:479.548CDK6/9-IN-1
CAS:CDK6/9-IN-1, an oral dual inhibitor of CDK6/9, has IC50s of 40.5nM (CDK6) and 39.5nM (CDK9).Fórmula:C22H25ClN8OForma y color:SolidPeso molecular:452.95Anticancer agent 264
Anticanceragent 264 (Compound 5w) is an anticancer compound that exhibits significant antiproliferative activity in tumor cell lines, with an IC50 range of 7.5-33.67 μM. It notably induces cell cycle arrest at the G2/M phase in MDA-MB-231, MIA PaCa-2, and DU-145 cell lines. This compound reduces key cell cycle proteins CDK1, CDK2, and Cyclin B1 in a dose-dependent manner and has strong binding activity with differentiation inhibitors and DNA-binding proteins. Anticanceragent 264 is useful for research in the cancer disease domain.Fórmula:C23H18ClF5N6OForma y color:SolidPeso molecular:524.87SNX7
CAS:SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.Fórmula:C15H14N2OPureza:99.96%Forma y color:SolidPeso molecular:238.28PROTAC CDK9 degrader-7
CAS:PROTAC CDK9 degrader-7 is a proteolysis-targeting chimera (PROTAC) specifically designed to target and mediate the degradation of Cyclin-Dependent Kinase 9 (Fórmula:C43H50Cl2N8O9Forma y color:SoildPeso molecular:893.81CP-07
CP-07 is a selective and effective PROTAC CDK9 degrader (DC50: 43 nM), demonstrating inhibition of 22RV1 cell proliferation (IC50: 62 nM) and colony formationFórmula:C45H48N6O8Pureza:98%Forma y color:SolidPeso molecular:800.9JH-XI-10-02
CAS:JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.Fórmula:C53H69N5O9Pureza:98%Forma y color:SolidPeso molecular:920.161CDK12-IN-6
CAS:CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).Fórmula:C20H21F2N9Forma y color:SolidPeso molecular:425.448NU6102
CAS:NU6102 is a CDK2 inhibitor with antitumor activity against CDK1/cyclinB, CDK1/CDK2, CDK4, DYRK1A , PDK1, and ROCKII, and it can be used to study rectal cancer.Fórmula:C18H22N6O3SPureza:99.76%Forma y color:SolidPeso molecular:402.47LDC4297
CAS:LDC4297 (LDC044297) is a potent and selective CDK7 inhibitor.Fórmula:C23H28N8OPureza:98.25%Forma y color:SolidPeso molecular:432.52Ribociclib hydrochloride
CAS:Ribociclib hydrochloride (LEE011 HCl) is a selective, orally active cyclin-dependent kinase CDK4/6 inhibitor (IC50=10/39 nM) that inhibits proliferation.Fórmula:C23H31ClN8OPureza:99.87%Forma y color:SolidPeso molecular:471CDK5-IN-3
CAS:CDK5-IN-3 is a selective and potent CDK5 inhibitor that inhibits CDK5/p25 and CDK2/CycA, and can be used in the study of cancer.Fórmula:C22H26N4OPureza:98.21%Forma y color:SolidPeso molecular:362.47Palbociclib-d8
CAS:Palbociclib-d8 (PD 0332991 D8) is the deuterated form of Palbociclib. Palbociclib is a CDK inhibitor that inhibits CDK4 and CDK6.Fórmula:C24H21D8N7O2Pureza:98%Forma y color:SolidPeso molecular:455.58PROTAC CDK9 Degrader-1
CAS:PROTAC CDK9 Degrader-1 is a selective PROTAC-based CDK9 degrader, composed of a Cereblon ligand and a CDK ligand.Fórmula:C33H35N5O7Pureza:95.1%Forma y color:SolidPeso molecular:613.66TG-693
CAS:TG-693, Oral CLK1 inhibitor, promotes exon 31 skipping of dystrophin gene, inhibits CLK1 substrate phosphorylation, for Duchenne muscular dystrophy.Fórmula:C12H9N3Pureza:99.81%Forma y color:SolidPeso molecular:195.23NCT02
CAS:NCT02 degrades cyclin K, leading to CCNK and CDK12 degradation, potentially aiding metastatic CRC research.Fórmula:C17H16N2O2SForma y color:SolidPeso molecular:312.39Palbociclib hydrochloride
CAS:Palbociclib hydrochloride is the salt form of Palbociclib, a selective and orally available CDK4 and CDK6 inhibitor for breast and hepatocellular carcinoma.Fórmula:C24H31Cl2N7O2Pureza:99.89%Forma y color:SolidPeso molecular:520.46
